FTRE
Fortrea Holdings Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.53
P/S
0.32
EV/EBITDA
-0.95
DCF Value
$-4.61
FCF Yield
10.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
16.4%
Operating Margin
-19.8%
Net Margin
-36.2%
ROE
-152.2%
ROA
-87.0%
ROIC
-29.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $660.5M | $-32.5M | $-0.36 |
| FY 2025 | $2.72B | $-986.2M | $-10.81 |
| Q3 2025 | $701.3M | $-15.9M | $-0.17 |
| Q2 2025 | $710.3M | $-374.9M | $-4.14 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.77
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.